The company can now sell their biologic for ulcerative colitis in a subcutaneous form on the US market.

Our ‘Navigating the Regulatory Landscape’ eBook has been designed to provide you with invaluable insights into the intricacies of regulations & policies surrounding the challenges and opportunities of Real-World Data, genome editing, biomedical informatics, manufacturing and many more.

What are the regulatory considerations that need to be made in the clinic for oligonucleotide therapies? What's the existing guidance for this emerging modality?

Here, we investigate some of the main trends and challenges in peptide bioanalysis such as non-specific binding, and look at how they can be circumvented.

Amgen and Synaffix's partnership aims to revolutionise cancer treatment by developing highly targeted antibody-drug conjugates (ADCs).

As medical research that is founded on nucleic acids continues to progress, we take a step back to look at the man who first discovered nucleic acids.

F-star Therapeutics and Takeda are partnering to develop next-generation multi-specific antibodies for cancer immunotherapy, building on F-star's advanced platforms.